Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise in fighting tough head and neck cancers

NCT ID NCT07524452

Recruiting now Disease control Sponsor: Ming-Yuan Chen Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated Apr 24, 2026 · Updated 2 times

Summary

This study tests whether adding the drug becotatug vedotin to a standard immunotherapy (PD-1 inhibitor) works better than the immunotherapy alone for people with a certain type of advanced head and neck cancer that can be removed by surgery. About 430 adults with EGFR-positive, CPS≥1 tumors will be randomly assigned to one of the two treatment groups. The main goal is to see if the combination helps patients live longer without the cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Fifth Affiliated Hospital,Sun Yat-sen University

    RECRUITING

    Zhuhai, Guangdong, 519099, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA